血清乳酸脱氢酶的变化与接受厄洛替尼治疗的晚期非小细胞肺癌患者的预后相关。
Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib.
作者信息
Fiala Ondrej, Pesek Milos, Finek Jindrich, Topolcan Ondrej, Racek Jaroslav, Svaton Martin, Kucera Radek, Minarik Marek, Benesova Lucie, Bortlicek Zbynek, Chloupkova Renata, Poprach Alexandr, Buchler Tomas
机构信息
Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
Department of Pneumology, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
出版信息
Anticancer Res. 2016 May;36(5):2459-65.
BACKGROUND
Serum lactate dehydrogenase (LDH) has been reported as a prognostic biomarker in malignant diseases. However, little is known on the dynamics of serum LDH levels during systemic treatment. We focused on the association of changes in serum LDH with outcome of patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib.
PATIENTS AND METHODS
Clinical data of 309 patients were analyzed. Serum samples were collected within one week before initiation and after one month of treatment.
RESULTS
The change in serum LDH during the first month of erlotinib treatment was independently associated with disease control rate (p=0.006), progression-free survival (PFS) (p=0.010) and overall survival (OS) (p<0.001).
CONCLUSION
LDH is a commonly used serum biomarker, that is cheap and easy to detect. The results of our study suggest that the change in LDH serum level during the first month is a surrogate marker on the efficacy of erlotinib in patients with advanced NSCLC.
背景
血清乳酸脱氢酶（LDH）已被报道为恶性疾病的一种预后生物标志物。然而，关于全身治疗期间血清LDH水平的动态变化知之甚少。我们重点关注血清LDH变化与接受厄洛替尼治疗的晚期非小细胞肺癌（NSCLC）患者预后的关联。
患者与方法
分析了309例患者的临床资料。在开始治疗前一周内及治疗一个月后采集血清样本。
结果
厄洛替尼治疗第一个月期间血清LDH的变化与疾病控制率（p = 0.006）、无进展生存期（PFS）（p = 0.010）和总生存期（OS）（p < 0.001）独立相关。
结论
LDH是一种常用的血清生物标志物，价格便宜且易于检测。我们的研究结果表明，第一个月期间LDH血清水平的变化是晚期NSCLC患者中厄洛替尼疗效的替代标志物。
Zotero 插件